[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,338,559
  • Shares Outstanding, K 96,643
  • Annual Sales, $ 7,500 K
  • Annual Income, $ -345,910 K
  • EBIT $ -373 M
  • EBITDA $ -371 M
  • 60-Month Beta 0.74
  • Price/Sales 714.00
  • Price/Cash Flow N/A
  • Price/Book 7.36

Options Overview Details

View History
  • Implied Volatility 47.97% (-1.24%)
  • Historical Volatility 31.64%
  • IV Percentile 17%
  • IV Rank 8.91%
  • IV High 176.33% on 02/20/26
  • IV Low 35.42% on 05/21/25
  • Expected Move (DTE 20) 1.96 (3.54%)
  • Put/Call Vol Ratio 44.50
  • Today's Volume 91
  • Volume Avg (30-Day) 447
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 13,776
  • Open Int (30-Day) 40,488
  • Expected Range 53.29 to 57.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.17
  • Number of Estimates 8
  • High Estimate $-1.07
  • Low Estimate $-1.32
  • Prior Year $-0.83
  • Growth Rate Est. (year over year) -40.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.62 +3.02%
on 03/30/26
59.99 -7.92%
on 04/14/26
+1.86 (+3.48%)
since 03/24/26
3-Month
40.29 +37.09%
on 02/05/26
63.95 -13.62%
on 03/10/26
+13.48 (+32.28%)
since 01/23/26
52-Week
28.19 +95.96%
on 05/30/25
63.95 -13.62%
on 03/10/26
+17.04 (+44.61%)
since 04/24/25

Most Recent Stories

More News
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly...

XENE : 55.24 (-0.31%)
Xenon to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 55.24 (-0.31%)
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term...

XENE : 55.24 (-0.31%)
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 55.24 (-0.31%)
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 55.24 (-0.31%)
Xenon Pharmaceuticals Announces Proposed Public Offering

VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 55.24 (-0.31%)
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)...

XENE : 55.24 (-0.31%)
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 55.24 (-0.31%)
Xenon Pharmaceuticals: Q4 Earnings Snapshot

Xenon Pharmaceuticals: Q4 Earnings Snapshot

XENE : 55.24 (-0.31%)
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026 Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with...

XENE : 55.24 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan...

See More

Key Turning Points

3rd Resistance Point 57.01
2nd Resistance Point 56.28
1st Resistance Point 55.76
Last Price 55.24
1st Support Level 54.52
2nd Support Level 53.79
3rd Support Level 53.27

See More

52-Week High 63.95
Last Price 55.24
Fibonacci 61.8% 50.29
Fibonacci 50% 46.07
Fibonacci 38.2% 41.85
52-Week Low 28.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.